Continuous outcome estimation in N-of-1 trials for accelerated decision-making

Area of Science:

• Clinical Trials
• Biostatistics
• Pharmacology

Background:

• N-of-1 trials assess individual treatment effects via repeated crossovers.
• Extended trial durations can increase patient burden and discontinuation rates.
• Early identification of responders/non-responders is theoretically possible.

Purpose of the Study:

• To evaluate continuous treatment effect estimation in N-of-1 trials.
• To determine the value of Bayesian hypothesis testing for accelerating clinical decisions.
• To refine N-of-1 study termination criteria.

Main Methods:

• Simulated an N-of-1 trial for severe epilepsy.
• Continuously analyzed three neurological N-of-1 trials with Bayesian hypothesis testing.
• Utilized a minimally clinically important threshold (30% seizure reduction).
• Compared trial durations based on Bayesian evidence versus original durations.

Main Results:

• Continuous estimation reduced trial duration by 9.5%–35% in two cases.
• Timing of strong evidence for treatment effects varied between Bayesian testing and clinical thresholds.
• More data points and intervention crossovers increased estimate certainty.

Conclusions:

• Continuous outcome estimation expedites treatment efficacy decisions compared to end-of-trial analysis.
• Combining Bayesian hypothesis testing and clinical significance thresholds enhances N-of-1 trial outcomes.